Texas to create response team to combat New World screwworms
According to the Centers for Disease Control and Prevention, New World screwworms are a species of fly larvae that infest and feed off the flesh of warm-blooded animals.
In a news release, Abbott said, 'The mission for the Response Team is clear: to lead Texas' prevention and response efforts and ensure that Texas remains informed, prepared, and aligned to prevent the re-emergence of this destructive parasite.'
The Texas Parks and Wildlife Department (TPWD) and the Texas Animal Health Commission (TAHC) are responsible for establishing the Texas New World Screwworm Response Team.
'As a border state, Texas represents the first line of defense against the potential re-entry of this harmful pest into the United States,' Abbott wrote in a letter to TPWD and TAHC. 'Texas played a critical role in eradicating this pest from the United States in the 1960s and will do so again if the need arises.'
Agriculture Secretary Brooke Rollins recently announced a multi-national program to stop the spread of screwworms.
The U.S. planned to invest $8.5 million in a dispersal site from Moore Air Base and $20 million in a facility in Mexico that produces sterilized screwworms. The insects will then be released by planes over Mexico to stop them from coming to the U.S.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
20 hours ago
- The Hill
Texas Senate passes bill targeting makers of abortion-inducing drugs
AUSTIN (KXAN) — Senate Bill 6, which aims to 'protect unborn children,' passed the Texas Senate on Tuesday. SB 6 would prohibit the manufacture, distribution, mailing, transporting, delivery and prescribing of abortion-inducing pills, as well as allow private citizens in Texas to file suit against people or companies that manufacture or distribute abortion-inducing pills in the state. Abortion is already almost totally banned in Texas. The bill was filed by Sen. Brian Hughes, R-Tyler. A similar bill passed the Senate during the regular session; however, it died in the House. 'The moms are victims here,' Hughes said. 'What we will go after with SB 6 is the manufacturers and the distributors of these drugs that are making them for the purpose of illegal abortions.' In response to the bill's passage, Lt. Gov. Dan Patrick said protecting life was a priority of his and the Texas Senate. 'We passed SB 6 … to ensure that abortion-inducing drugs are not distributed in Texas for the purpose of obtaining an illegal abortion,' Patrick said. 'The Texas Senate will continue passing this pro-life protection each legislative session.'
Yahoo
2 days ago
- Yahoo
SetPoint Medical secures $140M to fund neuromodulation for arthritis
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: SetPoint Medical said Monday that it raised $140 million to fund commercialization of its neuromodulation system to treat rheumatoid arthritis in a financing that included contributions from Abbott and Boston Scientific. SetPoint's implantable device received Food and Drug Administration approval in July as a treatment option for people who do not respond to, or cannot tolerate, biologic or targeted drug therapies. CEO Murthy Simhambhatla said SetPoint plans to introduce the system in some U.S. cities this year, with an expanded rollout across the country to follow beginning in early 2026. Dive Insight: SetPoint's device, which is implanted in the neck, delivers once-a-day electrical stimulation to the vagus nerve to activate the body's anti-inflammatory pathways. Development of the system was built on research by Kevin Tracey at the Feinstein Institutes for Medical Research, Northwell Health's research arm, demonstrating the role of the vagus nerve in controlling inflammation. Tracey founded SetPoint in 2007. The FDA approved SetPoint's device with support from the 242-patient REST-RA clinical trial, which showed safety and effectiveness. Simhambhatla has said SetPoint will work with providers and payers to make the treatment accessible to their patients. To prepare for commercialization, SetPoint said it named Erik Styacich, former vice president of sales for neuromodulation company Valencia Technologies, as vice president of sales and Spencer Bailey as vice president of market access and reimbursement. Bailey held similar roles at other neuromodulation companies, including MicroTransponder. SetPoint said the $140 million in private funding included $25 million in a second tranche of its Series C round and $115 million in its Series D financing led by Elevage Medical Technologies and Ally Bridge Group. The company said Josh Makower joined its board of directors as a representative of Elevage, and Kevin Reilly, managing director and head of medtech investments at Ally Bridge, also joined the board. New investors Northwell Health, SPRIG Equity and an undisclosed strategic investor also participated in the Series D financing. Returning investors included Abbott, Boston Scientific and several others. SetPoint plans to evaluate the technology for other autoimmune conditions, including multiple sclerosis and Crohn's disease. Recommended Reading Apreo raises $130M for pivotal trial of emphysema device
Yahoo
2 days ago
- Yahoo
Invacare, NOVA, Inogen, Thermo Fisher Scientific, Abbott, Medtronic, Baxter, B. Braun, Boston Scientific, BD
The United States Durable Medical Equipment Market is projected to grow at a CAGR of 5.03% from 2025 to 2033, reaching $97.10 billion by 2033, driven by rising chronic diseases, an aging population, and increased home healthcare demand. Key segments include personal mobility devices and monitoring and therapeutic equipment, with top players like Invacare, Abbott, and Medtronic leading innovations. California and New York are vibrant markets due to their demographics and healthcare infrastructure. Technological advances in smart devices and telehealth enhance market growth, though high costs and regulatory hurdles pose challenges for new entrants. U.S. Durable Medical Equipment Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "United States Durable Medical Equipment Market - Patient Care & Forecast 2025-2033" report has been added to States Durable Medical Equipment Market is expected to grow at a CAGR of 5.03% from 2025 to 2033 to reach US$ 97.10 billion by 2033, from US$ 62.43 billion in 2024 Growth is fueled by increasing chronic disease prevalence, a growing aging population, home healthcare demand, and technologic improvements in mobility aids, monitoring devices, and therapeutic equipment. DME plays a critical function in improving the quality of life for patients with chronic illnesses, disabilities, or convalescing at home following surgery or hospitalization. For example, patient mobility aids such as scooters and crutches assist patients in getting around safely, while respiratory devices provide proper oxygenation for patients with breathing impairments. Hospital beds used at home support and comfort bedridden most insurance programs, including Medicare, DME requires a physician's prescription and determination of medical necessity. Its sole reason for existence is to deliver therapeutic benefit, facilitate independence, and prevent the necessity of prolonged Drivers in the United States Durable Medical Equipment Market Aging Population and Prevalence of Chronic DiseaseThe growing population of older Americans represents a key driver of DME demand. Geriatric populations are typically plagued by illnesses like arthritis, diabetes, and restricted mobility, necessitating devices such as wheelchairs, walkers, and glucose level monitors. As close to 77 million baby boomers reach senior age ranges, the demand for in-home and hospital-grade DME continues to grow. At the same time, chronic diseases afflict more than half of U.S. adults, driving demand for long-term medical support devices. As medical care moves towards proactive and supportive therapy, DME is instrumental in allowing chronically ill and aging populations to preserve the quality of life and remain of Home Healthcare ServicesHome healthcare is increasingly becoming an option of choice for patients, spurred on by increasing hospital bills and the convenience of being treated at home. Durable medical equipment like oxygen concentrators, hospital beds, and nebulizers plays a primary role in home therapies. Medicare, Medicaid, and private insurance pay more for home healthcare services, so DME is more accessible. This is also driven by technological advances that enable remote monitoring and portable medical solutions. More health services are moving out of the clinical setting and into the home, so the market for easy-to-use, small, and safe DME is going to expand dramatically, increasing patient independence and lowering the cost of institutional Advances in Medical DevicesMedical technology innovations are revolutionizing the DME environment, with devices becoming more efficient, lighter, and user-oriented. Innovative products like smart wheelchairs with wayfinding support, wireless glucose meters, and battery-powered suction pumps are more user-friendly and offer better health monitoring. Telehealth and smartphone app integration enables real-time data exchange between patients and caregivers. This has enhanced therapy outcomes and user interaction. Besides this, innovations in materials have resulted in stronger and more comfortable equipment. With patients and clinicians looking for easy-to-use and high-performance devices, manufacturers are investing in R&D, driving the development of next-generation DME solutions in the U.S. States Durable Medical Equipment Market Challenges Exorbitant Costs and Reimbursement ConstraintsThe high initial cost of durable medical equipment usually presents fiscal challenges to patients as well as healthcare providers. While numerous products fall within Medicare and Medicaid coverage, reimbursement is time-consuming and complicated. Limited budgets within healthcare centers and strict insurance requirements frequently prevent timely access to needed devices. Out-of-pocket costs for non-covered or advanced models discourage consumers. Moreover, changes in coverage policies and coding guidelines frequently impact providers' revenue stability. These conditions bring about access inequities and deter entry by new firms because of regulatory obstacles and price Compliance and Quality StandardsManufacturers and vendors of DME are subject to stringent regulations by the FDA, CMS (Centers for Medicare & Medicaid Services), and state health agencies. Compliance with labeling standards, manufacturing standards, and reporting and safety standards can be time-consuming and expensive. Quality-related approval and recall delays can profoundly affect brand reputation and the continuity of operations. Also, the constant need to revise products in order to comply with changing requirements is putting a further strain on R&D and logistics. It becomes challenging for smaller manufacturers to keep up with regulatory demands while competing on innovation and States Medical Wheelchairs MarketThe U.S. medical wheelchair market is increasing at a steady pace with the aging population, mobility disorders, and the increased demand for independent living. Manual and powered wheelchairs are commonly used among elderly people, disabled, and post-operative patients in home and clinical environments. Advances in technology such as powered tilt and recline, lightweight material, and joystick control have improved the comfort and functionality of wheelchairs. Medicare and Medicaid coverage for wheelchair prescriptions also expand accessibility. As orthopedic conditions and rehabilitation demands escalate, particularly in veterans and the elderly, demand for high-quality, tailored wheelchair alternatives also States Commodes and Toilets MarketCommodes and adaptive toilet aids are indispensable for preserving dignity and independence among the elderly and disabled. In the United States, this market is fueled by mounting demand for home care equipment, particularly for mobility or post-operative difficulties. Commodes exist in different configurations such as bedside, drop-arm, and rolling commodes suited to various care requirements. Hospital, nursing home, and home environments are common usage sites. Features like height-adjustable designs, splash guards, and cleanability features have enhanced cleanliness and ease of use. With the rising trend of aging-in-place, sales of commodes will follow suit. Key Players Analysis | Overviews, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Invacare Corporation NOVA Medical Products Inogen, Inc. Thermo Fisher Scientific Inc. Abbott Medtronic Baxter B. Braun SE Boston Scientific Corporation BD Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $62.43 Billion Forecasted Market Value (USD) by 2033 $97.1 Billion Compound Annual Growth Rate 5.0% Regions Covered United States Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. United States Durable Medical Equipment Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product6.2 By End-User6.3 By States7. Product7.1 Personal Mobility Devices7.1.1 Wheelchairs7.1.1.1 Market Analysis7.1.1.2 Market Size & Forecast7.1.2 Scooters7.1.3 Walker and Rollators7.1.4 Canes and Crutches7.1.5 Others7.2 Bathroom Safety Devices and Medical Furniture7.2.1 Commodes and Toilets7.2.2 Mattress and Bedding Devices7.3 Monitoring and Therapeutic Devices7.3.1 Blood Sugar Monitors7.3.2 Continuous Passive Motion (CPM)7.3.3 Infusion Pumps7.3.4 Nebulizers7.3.5 Oxygen Equipment7.3.6 Continuous Positive Airway Pressure (CPAP)7.3.7 Suction Pumps7.3.8 Traction Equipment7.3.9 Others8. End-User8.1 Hospitals8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Specialty Clinics8.3 Ambulatory Surgical Centers8.4 Diagnostic Centers8.5 Home Healthcare8.6 Skilled Nursing Facilities8.7 Others9. Top 10 States9.1 California9.1.1 Market Analysis9.1.2 Market Size & Forecast9.2 Texas9.3 New York9.4 Florida9.5 Illinois9.6 Pennsylvania9.7 Ohio9.8 Georgia9.9 Washington9.10 New Jersey9.11 Rest of United States10. Value Chain Analysis11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Pricing Benchmark Analysis13.1 Invacare Corporation13.2 NOVA Medical Products13.3 Inogen, Inc.13.4 Thermo Fisher Scientific Inc.13.5 Abbott13.6 Medtronic13.7 Baxter13.8 B. Braun SE13.9 Boston Scientific Corporation13.10 BD14. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Durable Medical Equipment Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
